Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

PURPOSE: Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. PATIENTS AND METHODS: We eval...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Bardia, Aditya, Mayer, Ingrid A., Diamond, Jennifer R., Moroose, Rebecca L., Isakoff, Steven J., Starodub, Alexander N., Shah, Nikita C., O’Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M., Berlin, Jordan, Messersmith, Wells A., Ocean, Allyson J., Wegener, William A., Maliakal, Pius, Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Vahdat, Linda T.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2017
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559902/
https://ncbi.nlm.nih.gov/pubmed/28291390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.8297
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים